The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- (no title)
- New brain cancer treatment for children awarded FDA orphan status
- Dietary intake and the risk of monoclonal gammopathy of undetermined significance: results from the population-based iStopMM screening study
- Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
- Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
- Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications
- Vaginal swab test using AI found to accurately detect endometrial cancer
- 1st patient dosed in trial of all-oral myeloma treatment combo